ALZHEIMERS AND PARKINSONS-DISEASE - BRAIN LEVELS OF GLUTATHIONE, GLUTATHIONE DISULFIDE, AND VITAMIN-E

被引:127
作者
ADAMS, JD
KLAIDMAN, LK
ODUNZE, IN
SHEN, HC
MILLER, CA
机构
[1] UNIV SO CALIF, SCH MED, DEPT PATHOL, LOS ANGELES, CA 90033 USA
[2] UNIV SO CALIF, MED CTR, LOS ANGELES, CA 90033 USA
关键词
ALZHEIMERS DISEASE; PARKINSONS DISEASE; HUMAN BRAIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; VITAMIN-E;
D O I
10.1007/BF03159937
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Human brain levels of glutathione (GSH), glutathione disulfide (GSSG), and vitamin E were measured in neurologically normal control patients and two groups of patients with neurodegeneration: those with Alzheimer's disease (AD), and AD with some features of Parkinson's disease (AD-PD). Control brain samples contained GSH levels more than 50 times higher than GSSG. The levels of GSH were highest in the caudate nucleus and lowest in the medulla. In patients with AD or AD-PD, hippocampal levels of GSH were significantly higher than controls. Patients with AD also demonstrated high GSH levels in the midbrain compared to normal. In contrast, patients with AD-PD did not have significantly elevated GSH levels in this site. GSSG levels were not significantly different in any brain region between controls and diseased patients. In control brains, the medulla had higher levels of vitamin E than any other brain region. The caudate nucleus had the lowest levels, which were about half the levels in the medulla. Control levels of vitamin E in the midbrain were about 18.8-mu-g/g. In AD patients the midbrain levels of vitamin E doubled to 42.3-mu-g/g. This doubling also occurred in AD-PD patients where midbrain vitamin E levels increased to 44.0-mu-g/g. These results may indicate that compensatory increases in GSH and vitamin E levels occur following damage to specific brain regions in patients with AD or AD-PD.
引用
收藏
页码:213 / 226
页数:14
相关论文
共 46 条
  • [1] ADAMS JD, 1989, RES COMMUN SUBSTANCE, V10, P169
  • [2] ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749
  • [3] BERGERON C, 1989, Alzheimer Disease and Associated Disorders, V3, P197, DOI 10.1097/00002093-198900000-00002
  • [4] PARKINSON DISEASE, DEMENTIA, AND ALZHEIMER-DISEASE - CLINICOPATHOLOGICAL CORRELATIONS
    BOLLER, F
    MIZUTANI, T
    ROESSMANN, U
    GAMBETTI, P
    [J]. ANNALS OF NEUROLOGY, 1980, 7 (04) : 329 - 335
  • [5] A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS
    BROWN, MS
    GOLDSTEIN, JL
    [J]. SCIENCE, 1986, 232 (4746) : 34 - 47
  • [6] PATHOLOGICAL CORRELATES OF DEMENTIA IN PARKINSONS-DISEASE
    CHUI, HC
    MORTIMER, JA
    SLAGER, U
    ZAROW, C
    BONDAREFF, W
    WEBSTER, DD
    [J]. ARCHIVES OF NEUROLOGY, 1986, 43 (10) : 991 - 995
  • [7] ALTERATION OF ALPHA-TOCOPHEROL CONTENT IN THE DEVELOPING AND AGING PERIPHERAL NERVOUS-SYSTEM - PERSISTENCE OF HIGH CORRELATIONS WITH TOTAL AND SPECIFIC (N-6) POLYUNSATURATED FATTY-ACIDS
    CLEMENT, M
    BOURRE, JM
    [J]. JOURNAL OF NEUROCHEMISTRY, 1990, 54 (06) : 2110 - 2117
  • [8] DEXTER DT, 1987, LANCET, V2, P1219
  • [9] BASAL LIPID-PEROXIDATION IN SUBSTANTIA NIGRA IS INCREASED IN PARKINSONS-DISEASE
    DEXTER, DT
    CARTER, CJ
    WELLS, FR
    JAVOYAGID, F
    AGID, Y
    LEES, A
    JENNER, P
    MARSDEN, CD
    [J]. JOURNAL OF NEUROCHEMISTRY, 1989, 52 (02) : 381 - 389
  • [10] NEUROPATHOLOGIC AND CLINICAL-FEATURES OF PARKINSONS-DISEASE IN ALZHEIMERS-DISEASE PATIENTS
    DITTER, SM
    MIRRA, SS
    [J]. NEUROLOGY, 1987, 37 (05) : 754 - 760